Cari Overstreet, APRN
Psychiatric/Mental Health · Fort Smith, ARNPI 1912663758
Payments from drug & device makers
Across 104 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$654
- Neurocrine Biosciences, Inc.$359
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$245
- Otsuka America Pharmaceutical, Inc.$173
- Johnson & Johnson$155
- Idorsia Pharmaceuticals US Inc$97
- plus $203 from 6 others
What the payments were for
- Food & beverage$1,887100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $654 |
| Neurocrine Biosciences, Inc. | 18 | $359 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $245 |
| Otsuka America Pharmaceutical, Inc. | 13 | $173 |
| Johnson & Johnson | 8 | $155 |
| Idorsia Pharmaceuticals US Inc | 2 | $97 |
| Alkermes, Inc. | 2 | $52 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 3 | $37 |
| Tris Pharma Inc | 2 | $33 |
| Lundbeck LLC | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$136
How this compares
$1,887 in reported general payments places this provider in the 70th percentile of 359 psychiatric/mental health providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 69 | $225,086 |
| IngrezzaValbenazine Tosylate | 12 | $93,344 |
| AristadaAripiprazole Lauroxil | 13 | $43,698 |
| CaplytaLumateperone Tosylate | 20 | $33,416 |
| VraylarCariprazine Hcl | 22 | $32,259 |
| RexultiBrexpiprazole | 14 | $21,204 |
| VivitrolNaltrexone Microspheres | 12 | $20,456 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 35 | $5,002 |
| Chlorpromazine Hcl | 14 | $3,815 |
| Aripiprazole | 91 | $2,979 |
| Buspirone Hcl | 139 | $2,770 |
| Atomoxetine Hcl | 12 | $2,285 |
| Lurasidone Hcl | 33 | $2,218 |
| Ziprasidone Hcl | 17 | $2,117 |
| Quetiapine Fumarate | 163 | $2,094 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $155 | $225,08669 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $359 | $93,34412 claims |
| Alkermes, Inc.Aristada, Vivitrol | $52 | $64,15325 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $245 | $33,41620 claims |
| AbbVieVraylar | $654 | $32,25922 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $173 | $21,20414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 359 psychiatric/mental health providers in Arkansas.
Other psychiatric/mental health in Fort Smith
- Amber MobleyFort Smith$6K
- Christopher MilsteadFort Smith$6K
- Lauren AndrewsFort Smith$6K
- Debbie KochFort Smith$4K
- Kellie Berry HertFort Smith$4K
- Kelsey SalleeFort Smith$4K
- Christie KellerFayetteville$167K
- Stephanie BohannonFayetteville$32K
- Michael BelinSherwood$30K
- Sarah RamseySearcy$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.